Paloma Partners’s KALA BIO KALA Stock Holding History

Paloma Partners’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4	Closed	-$152K	–	1734
2018 Q2	$152K	Buy	+4	New	+$153K	﹤0.01%	1502

Other funds holding KALA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's KALA Position: Q3 2018 in Review

Paloma Partners sold out of KALA BIO (KALA) in Q3 2018, closing a stake of 4 shares — an estimated $152K sold.

Paloma Partners first reported a position in KALA in Q2 2018 and held it in 1 quarter. The position peaked at $152K in Q2 2018. 59 funds tracked by Wall St. Rank hold KALA as of Q3 2018.

Paloma Partners reported no remaining KALA BIO position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 4 KALA BIO shares in Q3 2018, an estimated $152K.
Paloma Partners first reported a position in KALA BIO in Q2 2018 and held it in 1 quarter.
Paloma Partners's KALA BIO position peaked at $152K in Q2 2018.
59 funds tracked by Wall St. Rank held KALA BIO as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.